Trial · NCT07603557
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 32
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs) | Up to approximately Month 36 | |
| Primary | Cohort 1 Part A: Number of participants with serious AEs (SAEs) | Up to approximately Month 36 | |
| Primary | Cohort 1 Part A: Number of participants with AEs of special interest (AESI) | Up to approximately Month 36 | |
| Primary | Cohort 1 Part A: Number of participants with clinically significant laboratory abnormalities | Up to approximately Month 36 | |
| Primary | Cohort 1 Part B: Hematologic Complete Response (CR) | Up to approximately Month 6 | |
| Secondary | Cohort 1 PART B: Hematologic Overall Response (OR) | Up to approximately Month 6 | |
| Secondary | Cohort 1 PART A and Cohort 2: Hematologic CR and OR | Up to approximately Month 6 | |
| Secondary | Cohort 1 PART B and Cohort 2: Number of participants with TEAEs | Up to approximately Month 36 | |
| Secondary | Cohort 1 PART B and Cohort 2: Number of participants with SAEs | Up to approximately Month 36 | |
| Secondary | Cohort 1 PART B and Cohort 2: Number of participants with AESIs | Up to approximately Month 36 | |
| Secondary | Cohort 1 PART B and Cohort 2: Number of participants with clinically significant laboratory abnormalities | Up to approximately Month 36 | |
| Secondary | Number of participants with Hematologic PR | Up to approximately Month 6 | |
| Secondary | Number of participants with Hematologic CR | Up to approximately Month 36 | |
| Secondary | Number of participants with Hematologic PR | Up to approximately Month 36 | |
| Secondary | Number of participants with Hematologic OR | Up to approximately Month 36 | |
| Secondary | Number of participants with Best Overall Response (BOR) | Up to approximately Month 36 | |
| Secondary | Number of participants with durable CR, PR and OR | Up to approximately 12 months from Zola-cel infusion | |
| Secondary | Time to First Response (TTR) | Up to approximately Month 36 | |
| Secondary | Time to First Complete Response (TTCR) | Up to approximately Month 36 | |
| Secondary | Duration of response (DOR) | Up to approximately Month 36 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07603557/registered